top of page

SFDA's Guidance on Data Requirements for the Renewal of Marketing Authorizations Drug Products

Writer's picture: Sharan MuruganSharan Murugan

This guideline aims to classify the requirements for submitting a renewal of marketing authorization and to provide applicants with recommendations on the data that may impact the assessment of their drug products.

This document has been developed to assist applicants in the preparation and submission of drug applications for renewal of marketing authorization .


Renewal applications should be reviewed carefully in light of the following notes


  1. Renewal applications renewal application: have to contain a consolidated version of the file, containing at least the documents listed below and presented in accordance with the appropriate headings and numbering of the eCTD format.

  2. Applicants should be aware that deficient documentation can lead to the rejection of the application. In addition, submitting redundant or irrelevant information may delay approval procedures.

This guideline considers issues associated with the processing of renewals with the aim of giving procedural guidance to marketing authorization holders (MAHs) and applies to all types of human medicinal product registration pathways that are described in the Regulatory Framework for Drugs Approval.


Click on the LINK to know more about Data Requirements for the Renewal.


Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page